Published in Infect Immun on May 01, 2000
Intimin-specific immune responses prevent bacterial colonization by the attaching-effacing pathogen Citrobacter rodentium. Infect Immun (2001) 1.34
Attenuated Salmonella enterica serovar Typhi expressing urease effectively immunizes mice against Helicobacter pylori challenge as part of a heterologous mucosal priming-parenteral boosting vaccination regimen. Infect Immun (2002) 1.33
Protective efficacy of anti-Helicobacter pylori immunity following systemic immunization of neonatal mice. Infect Immun (2003) 1.01
Enhancement of immune responses by an attenuated Salmonella enterica serovar Typhimurium strain secreting an Escherichia coli heat-labile enterotoxin B subunit protein as an adjuvant for a live Salmonella vaccine candidate. Clin Vaccine Immunol (2010) 0.90
Systemic Th1 immunization of mice against Helicobacter pylori infection with CpG oligodeoxynucleotides as adjuvants does not protect from infection but enhances gastritis. Infect Immun (2004) 0.88
Salmonella enterica serovar enteritidis ghosts carrying the Escherichia coli heat-labile enterotoxin B subunit are capable of inducing enhanced protective immune responses. Clin Vaccine Immunol (2014) 0.87
Trial Watch: DNA vaccines for cancer therapy. Oncoimmunology (2014) 0.86
Possible correlates of long-term protection against Helicobacter pylori following systemic or combinations of mucosal and systemic immunizations. Infect Immun (2007) 0.84
Expression, purification and immuno-characteristics of recombination UreB protein of H.pylori. World J Gastroenterol (2001) 0.83
Analysis of immune responses against H pylori in rabbits. World J Gastroenterol (2007) 0.80
Protective efficacy of recombinant urease B and aluminum hydroxide against Helicobacter pylori infection in a mouse model. FEMS Immunol Med Microbiol (2010) 0.78
Immunogenicity of Recombinant Helicobacter pylori Urease B Administered by Various Routes and with Different Adjuvants. Open Vaccine J (2009) 0.78
Bioactivity and immunological evaluation of LPS from different serotypes of Helicobacter pylori. Iran J Microbiol (2013) 0.77
Development of safe, effective and immunogenic vaccine candidate for diarrheagenic Escherichia coli main pathotypes in a mouse model. BMC Res Notes (2016) 0.77
Antigen 43/Fcε3 chimeric protein expressed by a novel bacterial surface expression system as an effective asthma vaccine. Immunology (2014) 0.77
Immunological response to parenteral vaccination with recombinant hepatitis B virus surface antigen virus-like particles expressing Helicobacter pylori KatA epitopes in a murine H. pylori challenge model. Clin Vaccine Immunol (2011) 0.76
Immunogenicity of a fusion protein comprising coli surface antigen 3 and labile B subunit of enterotoxigenic Escherichia coli. Iran Biomed J (2014) 0.75
New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development. Microbiol Rev (1983) 7.16
Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science (1995) 5.73
Gangliosides and membrane receptors for cholera toxin. Biochemistry (1973) 4.81
Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin. J Immunol (1984) 3.89
Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity. Infect Immun (1995) 3.22
Helicobacter pylori and gastroduodenal disease. Annu Rev Med (1992) 2.75
Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues. Infect Immun (1989) 2.74
Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology (1999) 2.72
Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med (1998) 2.70
Helper T cell subsets for immunoglobulin A responses: oral immunization with tetanus toxoid and cholera toxin as adjuvant selectively induces Th2 cells in mucosa associated tissues. J Exp Med (1993) 2.62
The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity. Eur J Immunol (1992) 2.52
Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems. Vaccine (1993) 2.37
Protection of germ-free mice from infection by Helicobacter felis after active oral or passive IgA immunization. Vaccine (1993) 2.36
Immunization of BALB/c mice against Helicobacter felis infection with Helicobacter pylori urease. Gastroenterology (1994) 2.35
Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses. Cell Immunol (1989) 2.15
A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity. Proc Natl Acad Sci U S A (1997) 2.07
Mucosal adjuvanticity and immunogenicity of LTR72, a novel mutant of Escherichia coli heat-labile enterotoxin with partial knockout of ADP-ribosyltransferase activity. J Exp Med (1998) 1.98
Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis (1995) 1.97
Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J Exp Med (1996) 1.75
Impaired mucosal immune responses in interleukin 4-targeted mice. J Exp Med (1995) 1.71
Helicobacter pylori infection in immunized mice lacking major histocompatibility complex class I and class II functions. Infect Immun (1999) 1.69
Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli labile enterotoxin. J Infect Dis (1996) 1.68
Immunisation against gastric helicobacter infection in a mouse/Helicobacter felis model. Lancet (1992) 1.66
Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci U S A (1994) 1.66
Comparison of intranasal inoculation of influenza HA vaccine combined with cholera toxin B subunit with oral or parenteral vaccination. Vaccine (1990) 1.62
Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity. J Exp Med (1997) 1.61
A simplified method for detecting the heat-labile enterotoxin of Escherichia coli. J Med Microbiol (1984) 1.61
Oral administration of cholera toxin-Sendai virus conjugate potentiates gut and respiratory immunity against Sendai virus. J Immunol (1988) 1.60
Skin immunization made possible by cholera toxin. Nature (1998) 1.55
Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect Immun (1998) 1.54
Intranasal immunogenicity and adjuvanticity of site-directed mutant derivatives of cholera toxin. Infect Immun (1997) 1.54
Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine. Infect Immun (1994) 1.51
New perspectives in vaccine development: mucosal immunity to infections. Infect Agents Dis (1993) 1.48
Adjuvant effect of cholera enterotoxin on the immune response of the mouse to sheep red blood cells. J Infect Dis (1972) 1.45
Antibody-independent protective mucosal immunity to gastric helicobacter infection in mice. Cell Immunol (1999) 1.43
Systemic immunization with urease protects mice against Helicobacter pylori infection. Vaccine (1998) 1.42
A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes. Proc Natl Acad Sci U S A (1997) 1.40
Whole cholera toxin and B subunit act synergistically as an adjuvant for the mucosal immune response of mice to keyhole limpet haemocyanin. Scand J Immunol (1990) 1.39
Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit. Proc Natl Acad Sci U S A (1996) 1.38
Induction of mucosal and systemic immune responses by intranasal immunization using recombinant cholera toxin B subunit as an adjuvant. Vaccine (1998) 1.35
What role does Helicobacter pylori play in gastric cancer? Gastroenterology (1997) 1.34
Transcutaneous immunization with bacterial ADP-ribosylating exotoxins as antigens and adjuvants. Infect Immun (1999) 1.32
Pathophysiologic effects of lethal and immunoregulatory doses of cholera enterotoxin in the mouse. J Immunol (1974) 1.31
A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nat Biotechnol (1998) 1.30
Cholera toxin adjuvant greatly promotes antigen priming of T cells. Eur J Immunol (1993) 1.29
Oral immunization against Helicobacter pylori. Infect Immun (1991) 1.27
Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine (1997) 1.26
Chronic active gastritis due to Helicobacter pylori in immunized gnotobiotic piglets. Gastroenterology (1992) 1.24
Role of receptor binding in toxicity, immunogenicity, and adjuvanticity of Escherichia coli heat-labile enterotoxin. Infect Immun (1997) 1.13
Immunization against natural Helicobacter pylori infection in nonhuman primates. Infect Immun (1998) 1.12
Role of GM1 binding in the mucosal immunogenicity and adjuvant activity of the Escherichia coli heat-labile enterotoxin and its B subunit. Immunology (1998) 1.11
Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys. Vaccine (1999) 1.00
Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin. Vaccine (1996) 0.99
Mutational analysis of the role of ADP-ribosylation activity and GM1-binding activity in the adjuvant properties of the Escherichia coli heat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin. Eur J Immunol (1998) 0.97
Recombinant cholera toxin B subunit is not an effective mucosal adjuvant for oral immunization of mice against Helicobacter felis. Immunology (1998) 0.97
Vaccination of gnotobiotic piglets against Helicobacter pylori. J Infect Dis (1998) 0.97
Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity. J Immunol (1999) 0.96
Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine. Vaccine (1994) 0.96
Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin. Vaccine (1998) 0.96
Prevention of autoimmune disease due to lymphocyte modulation by the B-subunit of Escherichia coli heat-labile enterotoxin. Proc Natl Acad Sci U S A (1997) 0.96
Intranasal immunization with liposomes induces strong mucosal immune responses in mice. Eur J Immunol (1995) 0.95
Immunogenicity of bacterial carbohydrates: cholera toxin modulates the immune response against dextran B512. Immunology (1997) 0.87
Induction of CD8+ cytotoxic T cells by immunization with killed influenza virus and effect of cholera toxin B subunit. Vaccine (1993) 0.86
A comparison of natural and recombinant cholera toxin B subunit as stimulatory factors in intranasal immunization. Vaccine (1997) 0.84
Effect of cholera toxin on vaccine-induced immunity and infection in murine schistosomiasis mansoni. Infect Immun (1993) 0.80
Relationship between a low toxicity of the mutant A subunit of enterotoxigenic Escherichia coli enterotoxin and its strong adjuvant action. Immunology (1997) 0.78
Lassa virus isolation from Mastomys natalensis rodents during an epidemic in Sierra Leone. Science (1974) 3.86
A hospital epidemic of Lassa fever in Zorzor, Liberia, March-April 1972. Am J Trop Med Hyg (1973) 3.71
Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases. Lancet (2001) 3.09
Human immunodeficiency virus-specific cytotoxic responses of seropositive individuals: distinct types of effector cells mediate killing of targets expressing gag and env proteins. J Virol (1989) 3.05
Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. II. Clinical observations and virological studies on selected hospital cases. Am J Trop Med Hyg (1974) 2.95
Immunoglobulin M antibody capture enzyme-linked immunosorbent assay for diagnosis of St. Louis encephalitis. J Clin Microbiol (1984) 2.95
Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology (1999) 2.72
Immunization of mice with urease vaccine affords protection against Helicobacter pylori infection in the absence of antibodies and is mediated by MHC class II-restricted responses. J Exp Med (1998) 2.70
Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ (1981) 2.36
Lassa fever. Trop Doct (1973) 2.32
Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J Virol (1986) 2.26
Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis (1995) 1.97
Lassa fever in the Eastern Province of Sierra Leone, 1970-1972. I. Epidemiologic studies. Am J Trop Med Hyg (1974) 1.92
Dissension in the ranks. Can Med Assoc J (1981) 1.91
Clinical presentation of Lassa fever cases during the hospital epidemic at Zorzor, Liberia, March-April 1972. Am J Trop Med Hyg (1973) 1.91
Lassa fever: review of epidemiology and epizootiology. Bull World Health Organ (1975) 1.86
Therapeutic immunization against Helicobacter mustelae in naturally infected ferrets. Gastroenterology (1996) 1.84
Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol (2000) 1.79
The 1970 yellow fever epidemic in Okwoga District, Benue Plateau State, Nigeria. 3. Serological responses in persons with and without pre-existing heterologous group B immunity. Bull World Health Organ (1973) 1.79
Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J Exp Med (1996) 1.75
Molecular characterization of a 23-kilodalton major antigen secreted by Toxoplasma gondii. Proc Natl Acad Sci U S A (1989) 1.73
Construction, safety, and immunogenicity in nonhuman primates of a chimeric yellow fever-dengue virus tetravalent vaccine. J Virol (2001) 1.73
Lassa fever in Britain: an imported case. Br Med J (1973) 1.72
Effect of oral immunization with recombinant urease on murine Helicobacter felis gastritis. Infect Immun (1995) 1.66
Six epitopes reacting with human cytotoxic CD8+ T cells in the central region of the HIV-1 NEF protein. J Immunol (1991) 1.60
Lassa fever and Marburg virus disease. WHO Chron (1974) 1.58
Challenge model for Helicobacter pylori infection in human volunteers. Gut (2004) 1.57
Mode of entry of a neurotropic arbovirus into the central nervous system. Reinvestigation of an old controversy. Lab Invest (1983) 1.55
Rectal and intranasal immunizations with recombinant urease induce distinct local and serum immune responses in mice and protect against Helicobacter pylori infection. Infect Immun (1998) 1.54
Labile serum factor and its effect on arbovirus neutralization. Appl Microbiol (1971) 1.51
Detection of yellow fever virus in serum by enzyme immunoassay. Am J Trop Med Hyg (1984) 1.50
Genetic variation among dengue 2 viruses of different geographic origin. Virology (1983) 1.48
Arthropod-borne encephalitides in the Americas. Bull World Health Organ (1979) 1.47
Qualitative and quantitative analysis of human cytotoxic T-lymphocyte responses to HIV-1 proteins. AIDS (1992) 1.47
Neutralizing antibody responses in the major immunoglobulin classes to yellow fever 17D vaccination of humans. Am J Epidemiol (1971) 1.45
Antiviral (RNA) activity of selected Amaryllidaceae isoquinoline constituents and synthesis of related substances. J Nat Prod (1992) 1.43
Epidemic yellow fever caused by an incompetent mosquito vector. Trop Med Parasitol (1989) 1.43
An antigenic peptide of the HIV-1 NEF protein recognized by cytotoxic T lymphocytes of seropositive individuals in association with different HLA-B molecules. Eur J Immunol (1989) 1.43
Urban yellow fever epidemic in western Nigeria, 1987. Trans R Soc Trop Med Hyg (1990) 1.41
The Badgley report on the abortion law. Can Med Assoc J (1977) 1.39
Variation in virulence for mice and rhesus monkeys among St. Louis encephalitis virus strains of different origin. Am J Trop Med Hyg (1980) 1.38
Reevaluation of the western equine encephalitis antigenic complex of alphaviruses (family Togaviridae) as determined by neutralization tests. Am J Trop Med Hyg (1988) 1.38
Evaluation of formalin-inactivated Clostridium difficile vaccines administered by parenteral and mucosal routes of immunization in hamsters. Infect Immun (1995) 1.35
The composition and function of M cell apical membranes: implications for microbial pathogenesis. Semin Immunol (1999) 1.35
Gag-specific cytotoxic T lymphocytes from human immunodeficiency virus type 1-infected individuals: Gag epitopes are clustered in three regions of the p24gag protein. J Virol (1993) 1.33
Expression of heterologous genes in Mycobacterium bovis BCG: induction of a cellular response against HIV-1 Nef protein. Gene (1991) 1.32
Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE). J Virol (2001) 1.32
Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types. FEBS Lett (2000) 1.31
Recent isolations of Lassa virus from Nigerian rodents. Bull World Health Organ (1975) 1.31
Genetic heterogeneity of yellow fever virus strains from Africa and the Americas. J Gen Virol (1986) 1.30
Gastritis in urease-immunized mice after Helicobacter felis challenge may be due to residual bacteria. Gastroenterology (1997) 1.27
Variation among strains of St. Louis encephalitis virus: basis for a genetic, pathogenetic, and epidemiologic classification. Ann N Y Acad Sci (1980) 1.27
Adherence of Salmonella typhimurium to Caco-2 cells: identification of a glycoconjugate receptor. Infect Immun (1996) 1.27
Novel intranasal immunization techniques for antibody induction and protection of mice against gastric Helicobacter felis infection. Vaccine (1997) 1.26
Serum antitoxin antibodies mediate systemic and mucosal protection from Clostridium difficile disease in hamsters. Infect Immun (1999) 1.25
Yellow fever in the Gambia, 1978--1979: epidemiologic aspects with observations on the occurrence of orungo virus infections. Am J Trop Med Hyg (1980) 1.24
Safety and immunogenicity of increasing doses of a Clostridium difficile toxoid vaccine administered to healthy adults. Infect Immun (2001) 1.23
Laboratory transmission of eastern equine encephalomyelitis virus to chickens by chicken mites (Acari: Dermanyssidae). J Med Entomol (1993) 1.23
Dengue virus infections in Nigeria: a survey for antibodies in monkeys and humans. Trans R Soc Trop Med Hyg (1977) 1.22
Urease-specific monoclonal antibodies prevent Helicobacter felis infection in mice. Infect Immun (1995) 1.20
Geographic distribution and evolution of yellow fever viruses based on direct sequencing of genomic cDNA fragments. J Gen Virol (1994) 1.20
Imported Lassa fever--reexamining the algorithms. N Engl J Med (1990) 1.18
Lassa virus hepatitis. Observations on a fatal case from the 1972 Sierra Leone epidemic. Arch Pathol (1975) 1.16
[Sylvatic yellow fever in Africa recent advances and present approach (author's transl)]. Med Trop (Mars) (1981) 1.16
Vaccine development against dengue and Japanese encephalitis: report of a World Health Organization meeting. Vaccine (1997) 1.16
High-frequency mutations in a plasmid-encoded gas vesicle gene in Halobacterium halobium. Proc Natl Acad Sci U S A (1988) 1.15
A field study on the effects of Fort Morgan virus, an arbovirus transmitted by swallow bugs, on the reproductive success of cliff swallows and symbiotic house sparrows in Morgan County, Colorado, 1976. Am J Trop Med Hyg (1984) 1.15
Phenotypic and molecular analyses of yellow fever 17DD vaccine viruses associated with serious adverse events in Brazil. Virology (2001) 1.14
Dengue 2 virus envelope protein expressed by a recombinant vaccinia virus fails to protect monkeys against dengue. J Gen Virol (1988) 1.13
Genetic variation and microevolution of dengue 2 virus in Southeast Asia. Virology (1989) 1.13
Yellow fever vector live-virus vaccines: West Nile virus vaccine development. Trends Mol Med (2001) 1.13
Investigation of a possible yellow fever epidemic and serosurvey for flavivirus infections in northern Cameroon, 1984. Bull World Health Organ (1987) 1.12
Genetic and epidemiological studies of dengue type 2 viruses by hybridization using synthetic deoxyoligonucleotides as probes. J Gen Virol (1986) 1.12
Epidemic yellow fever in eastern Nigeria, 1986. Lancet (1988) 1.12
The role of NF-kappa B in TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis of melanoma cells. J Immunol (2001) 1.12
Recovery of Tonate virus ("Bijou Bridge" strain), a member of the Venezuelan equine encephalomyelitis virus complex, from Cliff Swallow nest bugs (Oeciacus vicarius) and nestling birds in North America. Am J Trop Med Hyg (1980) 1.11
Pathophysiologic correlations in a rhesus monkey model of yellow fever with special observations on the acute necrosis of B cell areas of lymphoid tissues. Am J Trop Med Hyg (1981) 1.11
Studies on California encephalitis in Minnesota. Am J Epidemiol (1970) 1.10
Characterization of Fort Morgan virus, an alphavirus of the western equine encephalitis virus complex in an unusual ecosystem. Am J Trop Med Hyg (1980) 1.09
Diagnosis of Lassa fever and the isolation and management of patients. Bull World Health Organ (1975) 1.09
Arbovirus investigations in Argentina, 1977-1980. IV. Serologic surveys and sentinel equine program. Am J Trop Med Hyg (1985) 1.09
Adaptation of bluetongue virus in mosquito cells results in overexpression of NS3 proteins and release of virus particles. Arch Virol (1995) 1.09
Geographic classification of dengue-2 virus strains by antigen signature analysis. Virology (1986) 1.08
Intranasal monoclonal IgA antibody to respiratory syncytial virus protects rhesus monkeys against upper and lower respiratory tract infection. J Infect Dis (1996) 1.07
Isotypic restriction of the antibody response to human immunodeficiency virus. AIDS Res Hum Retroviruses (1988) 1.07
Growth characteristics of the chimeric Japanese encephalitis virus vaccine candidate, ChimeriVax-JE (YF/JE SA14--14--2), in Culex tritaeniorhynchus, Aedes albopictus, and Aedes aegypti mosquitoes. Am J Trop Med Hyg (2000) 1.05
Assessment of Helicobacter pylori gene expression within mouse and human gastric mucosae by real-time reverse transcriptase PCR. Infect Immun (2001) 1.04
Sindbis virus isolations from Saudi Arabian mosquitoes. Trans R Soc Trop Med Hyg (1985) 1.04
Aedes albopictus in the United States: rapid spread of a potential disease vector. J Am Mosq Control Assoc (1988) 1.04
Importance of nonhuman primates in yellow fever epidemiology in Nigeria. Trop Geogr Med (1973) 1.03
Immunization of rhesus monkeys with a mucosal prime, parenteral boost strategy protects against infection with Helicobacter pylori. Vaccine (1999) 1.03
Targeted delivery of antigen to hamster nasal lymphoid tissue with M-cell-directed lectins. Infect Immun (1997) 1.02
Soil characteristics, heavy metal availability and vegetation recovery at a former metallurgical landfill: Implications in risk assessment and site restoration. Environ Pollut (2005) 1.02